These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

324 related items for PubMed ID: 19471252

  • 1. Clinically meaningful improvement in health-related quality of life in a randomized controlled trial of certolizumab pegol maintenance therapy for Crohn's disease.
    Feagan BG, Coteur G, Tan S, Keininger DL, Schreiber S.
    Am J Gastroenterol; 2009 Aug; 104(8):1976-83. PubMed ID: 19471252
    [Abstract] [Full Text] [Related]

  • 2. Randomised clinical trial: improvement in health outcomes with certolizumab pegol in patients with active Crohn's disease with prior loss of response to infliximab.
    Feagan BG, Sandborn WJ, Wolf DC, Coteur G, Purcaru O, Brabant Y, Rutgeerts PJ.
    Aliment Pharmacol Ther; 2011 Mar; 33(5):541-50. PubMed ID: 21223344
    [Abstract] [Full Text] [Related]

  • 3. Effects of adalimumab maintenance therapy on health-related quality of life of patients with Crohn's disease: patient-reported outcomes of the CHARM trial.
    Loftus EV, Feagan BG, Colombel JF, Rubin DT, Wu EQ, Yu AP, Pollack PF, Chao J, Mulani P.
    Am J Gastroenterol; 2008 Dec; 103(12):3132-41. PubMed ID: 18853973
    [Abstract] [Full Text] [Related]

  • 4. Clinical trial: the effects of certolizumab pegol therapy on work productivity in patients with moderate-to-severe Crohn's disease in the PRECiSE 2 study.
    Feagan BG, Reilly MC, Gerlier L, Brabant Y, Brown M, Schreiber S.
    Aliment Pharmacol Ther; 2010 Jun; 31(12):1276-85. PubMed ID: 20298497
    [Abstract] [Full Text] [Related]

  • 5. Maintenance therapy with certolizumab pegol for Crohn's disease.
    Schreiber S, Khaliq-Kareemi M, Lawrance IC, Thomsen OØ, Hanauer SB, McColm J, Bloomfield R, Sandborn WJ, PRECISE 2 Study Investigators.
    N Engl J Med; 2007 Jul 19; 357(3):239-50. PubMed ID: 17634459
    [Abstract] [Full Text] [Related]

  • 6. Evaluation of the meaningfulness of health-related quality of life improvements as assessed by the SF-36 and the EQ-5D VAS in patients with active Crohn's disease.
    Coteur G, Feagan B, Keininger DL, Kosinski M.
    Aliment Pharmacol Ther; 2009 May 01; 29(9):1032-41. PubMed ID: 19222413
    [Abstract] [Full Text] [Related]

  • 7. Validity, reliability, and responsiveness of the work productivity and activity impairment questionnaire in Crohn's disease.
    Reilly MC, Gerlier L, Brabant Y, Brown M.
    Clin Ther; 2008 Feb 01; 30(2):393-404. PubMed ID: 18343277
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Health-related quality of life during natalizumab maintenance therapy for Crohn's disease.
    Feagan BG, Sandborn WJ, Hass S, Niecko T, White J.
    Am J Gastroenterol; 2007 Dec 01; 102(12):2737-46. PubMed ID: 18042106
    [Abstract] [Full Text] [Related]

  • 10. Increased response and remission rates in short-duration Crohn's disease with subcutaneous certolizumab pegol: an analysis of PRECiSE 2 randomized maintenance trial data.
    Schreiber S, Colombel JF, Bloomfield R, Nikolaus S, Schölmerich J, Panés J, Sandborn WJ, PRECiSE 2 Study Investigators.
    Am J Gastroenterol; 2010 Jul 01; 105(7):1574-82. PubMed ID: 20234346
    [Abstract] [Full Text] [Related]

  • 11. Evaluation of a daily practice composite score for the assessment of Crohn's disease: the treatment impact of certolizumab pegol.
    Feagan BG, Hanauer SB, Coteur G, Schreiber S.
    Aliment Pharmacol Ther; 2011 May 01; 33(10):1143-51. PubMed ID: 21443536
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Certolizumab pegol for the treatment of Crohn's disease.
    Sandborn WJ, Feagan BG, Stoinov S, Honiball PJ, Rutgeerts P, Mason D, Bloomfield R, Schreiber S, PRECISE 1 Study Investigators.
    N Engl J Med; 2007 Jul 19; 357(3):228-38. PubMed ID: 17634458
    [Abstract] [Full Text] [Related]

  • 14. Certolizumab pegol for active Crohn's disease: a placebo-controlled, randomized trial.
    Sandborn WJ, Schreiber S, Feagan BG, Rutgeerts P, Younes ZH, Bloomfield R, Coteur G, Guzman JP, D'Haens GR.
    Clin Gastroenterol Hepatol; 2011 Aug 19; 9(8):670-678.e3. PubMed ID: 21642014
    [Abstract] [Full Text] [Related]

  • 15. Randomised clinical trial: certolizumab pegol for fistulas in Crohn's disease - subgroup results from a placebo-controlled study.
    Schreiber S, Lawrance IC, Thomsen OØ, Hanauer SB, Bloomfield R, Sandborn WJ.
    Aliment Pharmacol Ther; 2011 Jan 19; 33(2):185-93. PubMed ID: 21083671
    [Abstract] [Full Text] [Related]

  • 16. Comparison of two adalimumab treatment schedule strategies for moderate-to-severe Crohn's disease: results from the CHARM trial.
    Colombel JF, Sandborn WJ, Rutgeerts P, Kamm MA, Yu AP, Wu EQ, Pollack PF, Lomax KG, Chao J, Mulani PM.
    Am J Gastroenterol; 2009 May 19; 104(5):1170-9. PubMed ID: 19352339
    [Abstract] [Full Text] [Related]

  • 17. Efficacy and safety of certolizumab pegol plus methotrexate in Japanese rheumatoid arthritis patients with an inadequate response to methotrexate: the J-RAPID randomized, placebo-controlled trial.
    Yamamoto K, Takeuchi T, Yamanaka H, Ishiguro N, Tanaka Y, Eguchi K, Watanabe A, Origasa H, Shoji T, Sakamaki Y, van der Heijde D, Miyasaka N, Koike T.
    Mod Rheumatol; 2014 Sep 19; 24(5):715-24. PubMed ID: 24313916
    [Abstract] [Full Text] [Related]

  • 18. Successful treatment of moderate to severe plaque psoriasis with the PEGylated Fab' certolizumab pegol: results of a phase II randomized, placebo-controlled trial with a re-treatment extension.
    Reich K, Ortonne JP, Gottlieb AB, Terpstra IJ, Coteur G, Tasset C, Mease P.
    Br J Dermatol; 2012 Jul 19; 167(1):180-90. PubMed ID: 22413944
    [Abstract] [Full Text] [Related]

  • 19. Rapid and sustained improvements in health-related quality of life, fatigue, and other patient-reported outcomes in rheumatoid arthritis patients treated with certolizumab pegol plus methotrexate over 1 year: results from the RAPID 1 randomized controlled trial.
    Strand V, Mease P, Burmester GR, Nikaï E, Coteur G, van Vollenhoven R, Combe B, Keystone EC, Kavanaugh A.
    Arthritis Res Ther; 2009 Jul 19; 11(6):R170. PubMed ID: 19909548
    [Abstract] [Full Text] [Related]

  • 20. Association between plasma concentrations of certolizumab pegol and endoscopic outcomes of patients with Crohn's disease.
    Colombel JF, Sandborn WJ, Allez M, Dupas JL, Dewit O, D'Haens G, Bouhnik Y, Parker G, Pierre-Louis B, Hébuterne X.
    Clin Gastroenterol Hepatol; 2014 Mar 19; 12(3):423-31.e1. PubMed ID: 24184736
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.